These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 29044764)

  • 21. Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure.
    Kurella Tamura M; Gaussoin S; Pajewski NM; Zaharchuk G; Freedman BI; Rapp SR; Auchus AP; Haley WE; Oparil S; Kendrick J; Roumie CL; Beddhu S; Cheung AK; Williamson JD; Detre JA; Dolui S; Bryan RN; Nasrallah IM;
    Am J Kidney Dis; 2022 May; 79(5):677-687.e1. PubMed ID: 34543687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Outcomes After Intensive Blood Pressure Lowering: Findings From the SPRINT Randomized Clinical Trial.
    Berry JD; Nambi V; Ambrosius WT; Chen H; Killeen AA; Taylor A; Toto RD; Soliman EZ; McEvoy JW; Pandey A; Joshi PH; Blankenberg S; Kitzman DW; Ballantyne CM; de Lemos JA
    JAMA Cardiol; 2021 Dec; 6(12):1397-1405. PubMed ID: 34468696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Intensive vs Standard Blood Pressure Control and Incident Left Ventricular Conduction Disease: A Post Hoc Analysis of the SPRINT Randomized Clinical Trial.
    Frimodt-Møller EK; Vittinghoff E; Kaur G; Biering-Sørensen T; Soliman EZ; Marcus GM
    JAMA Cardiol; 2023 Jun; 8(6):612-616. PubMed ID: 37133829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Acute Kidney Injury with Cardiovascular Events and Death in Systolic Blood Pressure Intervention Trial.
    Dieter BP; Daratha KB; McPherson SM; Short R; Alicic RZ; Tuttle KR
    Am J Nephrol; 2019; 49(5):359-367. PubMed ID: 30939480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship Between Sarcopenia and Intensive Blood Pressure Control Efficacy and Safety: A Secondary Analysis of SPRINT.
    Mirzai S; Persits I; Kazibwe R; Gabani M; Seals A; Singleton MJ; Rikhi R; Chevli PA; Carbone S; Tang WHW; Yeboah J; Williamson JD; Kitzman DW; Herrington DM; Shapiro MD
    Hypertension; 2024 Aug; 81(8):e77-e87. PubMed ID: 38881460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modifying Effect of Statins on Fatal Outcomes in Chronic Kidney Disease Patients in the Systolic Blood Pressure Intervention Trial: A Post Hoc Analysis.
    Rivera M; Tamariz L; Suarez M; Contreras G
    Am J Nephrol; 2019; 49(4):297-306. PubMed ID: 30917364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy.
    Vaduganathan M; Pareek M; Kristensen AMD; Biering-Sørensen T; Byrne C; Almarzooq Z; Olesen TB; Olsen MH; Bhatt DL
    Eur J Heart Fail; 2021 Mar; 23(3):384-392. PubMed ID: 33448580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Intensive Systolic Blood Pressure Lowering on End-Stage Kidney Disease and Kidney Function Decline in Adults With Type 2 Diabetes Mellitus and Cardiovascular Risk Factors: A Post Hoc Analysis of ACCORD-BP and SPRINT.
    Tawfik YMK; Van Tassell BW; Dixon DL; Baker WL; Fanikos J; Buckley LF
    Diabetes Care; 2023 Apr; 46(4):868-873. PubMed ID: 36787937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial).
    Patel KK; Arnold SV; Chan PS; Tang Y; Pokharel Y; Jones PG; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28373269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensive vs Standard Blood Pressure Control in Adults 80 Years or Older: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
    Pajewski NM; Berlowitz DR; Bress AP; Callahan KE; Cheung AK; Fine LJ; Gaussoin SA; Johnson KC; King J; Kitzman DW; Kostis JB; Lerner AJ; Lewis CE; Oparil S; Rahman M; Reboussin DM; Rocco MV; Snyder JK; Still C; Supiano MA; Wadley VG; Whelton PK; Wright JT; Williamson JD
    J Am Geriatr Soc; 2020 Mar; 68(3):496-504. PubMed ID: 31840813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Intensive BP Control in CKD.
    Cheung AK; Rahman M; Reboussin DM; Craven TE; Greene T; Kimmel PL; Cushman WC; Hawfield AT; Johnson KC; Lewis CE; Oparil S; Rocco MV; Sink KM; Whelton PK; Wright JT; Basile J; Beddhu S; Bhatt U; Chang TI; Chertow GM; Chonchol M; Freedman BI; Haley W; Ix JH; Katz LA; Killeen AA; Papademetriou V; Ricardo AC; Servilla K; Wall B; Wolfgram D; Yee J;
    J Am Soc Nephrol; 2017 Sep; 28(9):2812-2823. PubMed ID: 28642330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers of Kidney Tubule Health, CKD Progression, and Acute Kidney Injury in SPRINT (Systolic Blood Pressure Intervention Trial) Participants.
    Bullen AL; Katz R; Jotwani V; Garimella PS; Lee AK; Estrella MM; Shlipak MG; Ix JH
    Am J Kidney Dis; 2021 Sep; 78(3):361-368.e1. PubMed ID: 33857535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
    Buckley LF; Dixon DL; Wohlford GF; Wijesinghe DS; Baker WL; Van Tassell BW
    Diabetes Care; 2017 Dec; 40(12):1733-1738. PubMed ID: 28947569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebral White Matter Hyperintensities, Kidney Function Decline, and Recurrent Stroke After Intensive Blood Pressure Lowering: Results From the Secondary Prevention of Small Subcortical Strokes ( SPS 3) Trial.
    Ikeme JC; Pergola PE; Scherzer R; Shlipak MG; Catanese L; McClure LA; Benavente OR; Peralta CA
    J Am Heart Assoc; 2019 Feb; 8(3):e010091. PubMed ID: 30686103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The SPRINT Research. A Randomized Trial of Intensive versus Standard Blood-Pressure Control].
    Widimský J
    Vnitr Lek; 2016 Jan; 62(1):44-7. PubMed ID: 26967236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Intensive Blood Pressure Control and Living Arrangement on Cardiovascular Outcomes by Race: Post Hoc Analysis of SPRINT Randomized Clinical Trial.
    Inoue K; Watson KE; Kondo N; Horwich T; Hsu W; Bui AAT; Duru OK
    JAMA Netw Open; 2022 Mar; 5(3):e222037. PubMed ID: 35285922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Lowering Diastolic Pressure in Patients With and Without Cardiovascular Disease: Analysis of the SPRINT (Systolic Blood Pressure Intervention Trial).
    Khan NA; Rabkin SW; Zhao Y; McAlister FA; Park JE; Guan M; Chan S; Humphries KH
    Hypertension; 2018 May; 71(5):840-847. PubMed ID: 29581214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Individual and Joint Effects of Pulse Pressure and Blood Pressure Treatment Intensity on Serious Adverse Events in the SPRINT Trial.
    Krishnaswami A; Kim DH; McCulloch CE; Forman DE; Maurer MS; Alexander KP; Rich MW
    Am J Med; 2018 Oct; 131(10):1220-1227.e1. PubMed ID: 29940151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary Biomarkers of Tubular Damage Are Associated with Mortality but Not Cardiovascular Risk among Systolic Blood Pressure Intervention Trial Participants with Chronic Kidney Disease.
    Jotwani VK; Lee AK; Estrella MM; Katz R; Garimella PS; Malhotra R; Rifkin DE; Ambrosius W; Freedman BI; Cheung AK; Raphael KL; Drawz P; Neyra JA; Oparil S; Punzi H; Shlipak MG; Ix JH;
    Am J Nephrol; 2019; 49(5):346-355. PubMed ID: 30939472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
    Leehey DJ; Zhang JH; Emanuele NV; Whaley-Connell A; Palevsky PM; Reilly RF; Guarino P; Fried LF;
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2159-69. PubMed ID: 26482258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.